If you have been reading about albumin conjugate and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-11. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
=== DCVJ, rigidity sensitive dyes === 4-(dicyanovinyl)julolidine (DCVJ) is a molecular rotor probe with fluorescence that is strongly dependent on the rigidity of its environment. When protein denatures, DCVJ increases in fluorescence. It has been reported to work with 40 mg/ml of antibody.
Anaerobic growth: Positive Voges Proskauer test: Positive Acid produced from D-glucose: Positive L-arabinose: Negative D-xylose: Negative D-mannitol: Negative Starch hydrolysis: Positive Nitrate reduction: Positive Degradation of tyrosine: Positive Growth at above 50 °C: Negative Use of citrate: Positive The Central Public Health Laboratory in the United Kingdom tests for motility, hemolysis, rhizoid growth, susceptibility to γ-phage, and fermentation of ammonium salt-based glucose but no mannitol, arabinose, or xylose.
Gemma Clair Collins (born 31 January 1981) is an English media personality and businesswoman. She rose to prominence whilst appearing on the ITV reality series The Only Way Is Essex (2011–2019) and went on to appear on various other reality television shows, including I'm a Celebrity...Get Me Out of Here! (2014), Celebrity Big Brother (2016), Celebs Go Dating (2018) and Dancing on Ice (2019). Known for her diva persona and alter-ego "the GC", she became the subject of several internet memes and is considered a prominent figure within the British hun subculture. A sales executive by trade, Collins created her own plus-size clothing brand and owned a fashion boutique in Brentwood, Essex, as well as releasing a fragrance and a line of cosmetics. She has also collaborated with numerous brands to endorse their products alongside her own. Collins published two autobiographies and starred in her own ITV reality television franchise Gemma Collins: Diva (2018–2020). She went on to host the eponymous The Gemma Collins Podcast (2019–2024), as well as its spin-off The Gemma Collins Love Lounge (2020–2021). In 2022, she fronted a Channel 4 television documentary, Gemma Collins: Self-Harm & Me, based on her personal experiences and embarked on a theatre tour, The GC's Big Night Out. In 2026, she appeared as a contestant on the second series of I'm a Celebrity... South Africa and is set to star in the Sky One reality series Gemma Collins: Everything. All At Once.
Sources: en.wikipedia.org
Tens of thousands of three-dimensional protein structures have been determined by X-ray crystallography and protein nuclear magnetic resonance spectroscopy (protein NMR) and a central question in structural bioinformatics is whether it is practical to predict possible protein–protein interactions only based on these 3D shapes, without performing protein–protein interaction experiments. A variety of methods have been developed to tackle the protein–protein docking problem, though it seems that there is still much work to be done in this field. Other interactions encountered in the field include Protein–ligand (including drug) and protein–peptide. Molecular dynamic simulation of movement of atoms about rotatable bonds is the fundamental principle behind computational algorithms, termed docking algorithms, for studying molecular interactions.
Many buildings in the city are classified as "historical monuments", but the 2000s marked the real recognition of Le Havre's architectural heritage. The city received the label "City of Art and History" in 2001, then in 2005 UNESCO inscribed the city of Le Havre as a World Heritage Site. The oldest building still standing in Le Havre is the Graville Abbey. The other medieval building in the city is the Chapel of Saint-Michel of Ingouville. Because of the bombing in 1944, heritage from the modern era is rare: Le Havre Cathedral, the Church of Saint Francis, the Museum of the Hotel Dubocage of Bleville, the House of the ship-owner and the old palace of justice (now the Natural History Museum) are concentrated in the Notre-Dame and Saint-François areas. The buildings of the 19th century testify to the maritime and military vocations of the city: the Hanging Gardens, the Fort of Tourneville, Vauban docks, and the Maritime Villa. The heritage of the 1950s and 1960s which were the work of the Auguste Perret workshop forms the most coherent architecture: the Church of Saint Francis and the Town Hall are the centrepieces. The all curved architecture of the "Volcano", designed by Oscar Niemeyer, contrasts with that of the rebuilt centre. Finally, the reconstruction of many districts is a showcase for the architecture of the 21st century. Among the achievements by renowned architects are the Chamber of Commerce and Industry (René and Phine Weeke Dottelond), Les Bains Des Docks (Jean Nouvel). °
== External links == "Prokineticin Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2011-05-16. Retrieved 2007-10-25. PROKR1+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) PROKR2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.